{"name":"Navigator Medicines, Inc.","slug":"navigator-medicines-inc","ticker":"","exchange":"","domain":"navigatormedicines.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPV2Ezc3A1TzhtTGNFTkVxaUJnUmtiOUxlYmo1cnBRXzlseFptdHEwZmdpVlh4a19uUzZ3Q0xSNzNrVm5yelB1dF9sdDdJal9KLVdlZ2lSREpPR3RfTVFkWUN2V29CUTg0cHZYMjJDMzQ0Q0xSQ1NwOHdZNDdFRXFMUGhla21oWFY2OUZPN2M2SHNtamxQMVAw?oc=5","date":"2026-03-20","type":"pipeline","source":"BioWorld News","summary":"Imbiologics crosses $1B market cap with Kosdaq debut - BioWorld News","headline":"Imbiologics crosses $1B market cap with Kosdaq debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNWUx3bGdweG00eXRxaGlpMGFMVGQtbGFHbk9IWVFpaGJlYkZvLWJkR3M3QkNTZlhZMlJrWVJ0YkxBdllkamdpNnZDM2lHRnYwMVM3OVJaMmdBWWJTMEt1WXR6Z29oNDE1SEEwMXBlWmNnd0NzRm5iSWh4Rl9BSkJlemhKNl9pcGg0ckNKMHVwQThkdw?oc=5","date":"2026-03-11","type":"deal","source":"Evrim Ağacı","summary":"IM Biologics Surges With Landmark IPO And Global Deals - Evrim Ağacı","headline":"IM Biologics Surges With Landmark IPO And Global Deals - Evrim Ağacı","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQcXg0MThtR1pJTFNmX0U2OEpCVC1BcXFLMUdmN3dsZEQ0ZWJ1ZGw1czRCczVqTFF6V28yRkxBLXRjQ0xWMkFWOXBaME85RXJRY3RvRGc3aWd2TGIwTVFIS1lCY3BkaHhmOF9Jai1sYWZTZVNuVXJDYVhmMmRVVUVWVzh4U1lXVzUtV1pFUzVoanZ0Q3NnNFlUWHJrcG5Cd0Z5Nnp3b2J6UE5FLTJYY1dF?oc=5","date":"2026-03-10","type":"pipeline","source":"medscape.com","summary":"Talking With Patients Who Have Chronic Spontaneous Urticaria - medscape.com","headline":"Talking With Patients Who Have Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNY0ZYMGloVTV4RFc4N0o0ZjdHZEoxRUF1SjByWkNTOUxFb01IRDNOVFRZXzI0Y2lBeFR4UFRKNlNFM0RrVlgxV1VYRkwyYXRKVmVXZDhuSHBSdXoxOEtoeEg3dFZQRlEzb0RTdlpWb1JPRFhrZG1ES0pVcWhQTVBmUNIBlAFBVV95cUxPaGJ3U2ZwMElyVU42eEJJMERnSnpJRVV1LVNJUWtUeW9kWTFlazJqTXBPOWhRUXJkWDNTY251ZWhzT0FrVnV1bWVKRG1vNHhhZWFGdmRzX29TSXBDVnBpdloyNVp1Q0I4bjBoaUxheTlFZmxXX3Fkc25xb2RwLXJIVzl0MkJ1WEdqVVJHWGNSQ3FwbkZD?oc=5","date":"2026-02-24","type":"deal","source":"Chosunbiz","summary":"IMBiologics targets KOSDAQ valuation, tests single-partner risk amid Sanofi race - CHOSUNBIZ - Chosunbiz","headline":"IMBiologics targets KOSDAQ valuation, tests single-partner risk amid Sanofi race - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQTnBjQzR4eXU0b0w4XzdmOXVyU3BSWElCREdaRURGc005dEw3MEV4Q05ndGc2NEtVTnhWa09xSmJKQUlneFlqcS1jZGVWcGh6cERLRENvWGRTYUdQRzRJR3RTWk5TTmNndlV2NWNHdUJrbXc3LXl4d2o4ZDVqcE1zUmt6cENLWk1uTjZYWFhSb0dHRkM0ZGNuUzNfTnI4ZGx3YkxkZExUZ0UxWWMzYVFjeVEteE5HT1VxWFdNS1lDT2RrbkFZR1pteTAyR2xqa0k?oc=5","date":"2026-02-04","type":"pipeline","source":"Sleep Review","summary":"SleepNavigator Secures Investment to Scale Sleep Care Platform Nationally - Sleep Review","headline":"SleepNavigator Secures Investment to Scale Sleep Care Platform Nationally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPMkpGcmFpdmtYanZuelNHWXJMd28teFBhNkZyeUo3QVF4R0I2NG9XZnozZ1p1ZF9IYXV6TWUzSUdOTXNlUlZ1ZU9vNlk3Y0xyMjZtdnFyOFByYXVqUFZMbkF5QVZuOGMtcGdaVGFtN29kbkw2Qy03VTJzUXRTVEdBbzREN3JULVBFc0d5cEk2WDRhUFhUQXc2UjZjV2dRblhCamZBVFRGRGRRcWxXanI0bVByYVh1Q3ZjSmphMTFScHV5bXZqWHVwRm5VcnRSYmNhc2FyNm5uQlJrMGsyVTRkQ2xLWE53NHRPNDlMNHU2d3d4cDdSNVhrLVJnN3RxdlAzSW9rQ2JMaWNiazNRLV84Tmp4VFBNNHJ1d29jY0FQbFlNZFNnVGx0d1dlSy1KdDNmUTFIYzVmems3LWgwSWR3UA?oc=5","date":"2026-01-08","type":"pipeline","source":"GlobeNewswire","summary":"Navigator Medicines Accelerates Anti OX-40L and TNFα - GlobeNewswire","headline":"Navigator Medicines Accelerates Anti OX-40L and TNFα","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPblFRNm5UZGFpNnFoMkpoVHNYS3FZZmdnMTZBbmx4RThfdUpoQmNPbi1GY1p2cXZBVjdOZWN0UVpHSFFSX1JyLWJwWVl5c3lZMC0wR2tLalZ3SmhRcWZGblROZDVFdUE4RVVlcV84Smk0Ym9JdXNlcWg4aTlPYTc0cHotaTc4eHQ1SGEzMXRwVEVPUXgzNGszWmxDSV9VN2I2Y29IRXBsVHJicFh5ckRxa0ZVdTByN2pReksxMVlua0JJVU9UdDRmcWZKRUlwYUY4VnAtNlZmTEZnUGFDRzEtUlFiQ0ZQZ3MwX1RzMkJiRQ?oc=5","date":"2025-09-10","type":"trial","source":"prnewswire.com","summary":"Senderra Specialty Pharmacy introduces a data-driven, patient-focused digital solution, Pharma Navigator - prnewswire.com","headline":"Senderra Specialty Pharmacy introduces a data-driven, patient-focused digital solution, Pharma Navigator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOdlgtUWJ2a2RRb09yd3Iyb3VsemVSWnlrWFJpV2NWN28ycTlxS285WFg0X0ctYzhKM3BudUxOcHlCRmQyTW9FX3hWbHpxUEMxWC1YNWV0Sy1GajBud1k4aGpDTUJXNHBwdjF6dktFaW5nTlVWZk1pejJqVVY5OS12RFF2MW1tS2lkS0k2U2xOSlFUMUNLV1E?oc=5","date":"2025-05-28","type":"pipeline","source":"hospitalnews.com","summary":"The role of drug access navigators in healthcare-systems pharmacy - hospitalnews.com","headline":"The role of drug access navigators in healthcare-systems pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBsek11cGE4eUZ2N2VTOENXT2JaeEY3ckZnQWpRNjZaanFza0xUX3NxLU82TWNqYWN6X2Myb0RfU0ZqQ0U2ZHdVWkczbmNEeEJGcG80SEVzcVduNURpX2g2dw?oc=5","date":"2024-09-04","type":"pipeline","source":"The Pharma Letter","summary":"Navigator Medicines - The Pharma Letter","headline":"Navigator Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOd1FJUXlhekY0VGktTl9tS3R6cXUyUE1CbGxXUTVfTjZ0M0o5WkZxaVBfNHFMelpfM2tkTDMzdm92OXR1TzJSSTZHVUZSNnN5TnFtR1lpeC1kNTF3NHFKN2w5alE4aTM1SEZlS1VVTkxRWmcyd0x0R244ZW5DSE85ZFpuR2ZiRS04dk5FdQ?oc=5","date":"2024-08-28","type":"pipeline","source":"Pharmaceutical Technology","summary":"Navigator secures $100m to develop antibody therapeutics - Pharmaceutical Technology","headline":"Navigator secures $100m to develop antibody therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2lFNWpEQlZ6S2FuUG80eFZMX29ocjAyV0gtbGliR3c4NUNIZHFINF9VSW4yak9mVi03N01kWUlraTVOVUpaQmliRUVaMVJpR25pS2VkRU8yV3ZtbnFCXzFxVGZNeFcyS3BiZ0hHTmlobXFGSjlIbExUd2ttTjYyNmtMTTVEUWc0cGVLM3BTUWpkSjFjTHR5LV9vQms1MWxfZWNDNnhsTHc1TmhxRk93M3VmTkQzTW5uTzlzc1F6eS10U2JFSUpDMHl3Z1hXN3F5Vzl3UU9B?oc=5","date":"2024-08-28","type":"pipeline","source":"BioSpace","summary":"Navigator Closes $100M Series A, Targets Autoimmune Market With Potential Best-in-Class Bispecific Antibody - BioSpace","headline":"Navigator Closes $100M Series A, Targets Autoimmune Market With Potential Best-in-Class Bispecific Antibody","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-08-27","type":"pipeline","source":"businesswire.com","summary":"Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases - ","headline":"Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Ant","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}